Clinical settings with tofacitinib in ulcerative colitis

被引：1

作者：

Taxonera, Carlos ^{[1
]}

Lopez, Daniel Carpio ^{[2
]}

Manas, Ana Cabez ^{[3
]}

del Val, Joaquin Hinojosa ^{[4
]}

机构：

[1] Hosp Clin Univ San Carlos, Res Inst Hosp Clin San Carlos IdISSC, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Madrid, Spain

[2] Complexo Hosp Univ Pontevedra, Galicia Hlth Res Inst IISGS, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Pontevedra, Spain

[3] Pfizer SLU Alcobendas, Med Dept, Madrid, Spain

[4] Hosp Vithas Virgen Consuelo, Inflammatory Bowel Dis Unit, Carrer Callosa En Sarria 12, Valencia 46007, Spain

来源：

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS | 2024年 / 116卷 / 09期

关键词：

Tofacitinib; Ulcerative colitis; Inflammatory bowel disease; Janus kinases; Efficacy; Safety; Immune-mediated diseases; Biologic agents; JANUS KINASE INHIBITOR; RHEUMATOID-ARTHRITIS; SAFETY DATA; PHASE-III; DERMATOMYOSITIS; PREFERENCES; GUIDELINES; EFFICACY; THERAPY; PLACEBO;

D O I：

10.17235/reed.2022.8660/2022

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

There are aspects of Janus kinase (JAK) inhibitors, specially tofacitinib, that distinguish them from other drugs used in the treatment of ulcerative colitis (UC), such as their oral administration, short half-life, and lack of immunogenicity. With the scientific evidence currently available, we should mention tofacitinib quick action, flexibility of use, and efficacy profile in patients regardless of whether these have previously been exposed to TNF inhibitors (anti-TNF drugs) or other biologic agents. Moreover, their safety profile is known and manageable although certain considerations and precautions should be made before and during treatpertaining to this drug like its use in the event of failure or intolerance to previous treatment with biologic agents concomitant immune-mediated diseases.

引用

页码：484 / 492

页数：9

共 68 条

[1]

Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), 2022, Ficha tecnica Xeljanz

[2]

Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), 2019, IPT 40/2019

[3]

Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), 2022, Notas de seguridad. Xeljanz (tofacitinib): nuevas precauciones de uso

[4] Comorbidities in inflammatory bowel disease: a call for action [J].

Argollo, Marjorie ;

Gilardi, Daniel ;

Peyrin-Biroulet, Carina ;

Chabot, Jean Francois ;

Peyrin-Biroulet, Laurent ;

Donese, Silvio .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08) :643-654

[5] Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study [J].

Berinstein, Jeffrey A. ;

Sheehan, Jessica L. ;

Dias, Michael ;

Berinstein, Elliot M. ;

Steiner, Calen A. ;

Johnson, Laura A. ;

Regal, Randolph E. ;

Allen, John I. ;

Cushing, Kelly C. ;

Stidham, Ryan W. ;

Bishu, Shrinivas ;

Kinnucan, Jami A. R. ;

Cohen-Mekelburg, Shirley A. ;

Waljee, Akbar K. ;

Higgins, Peter D. R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (10) :2112-+

[6] Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry [J].

Biemans, Vince B. C. ;

Sleutjes, Jasmijn A. M. ;

Vries, Annemarie C. ;

Bodelier, Alexander G. L. ;

Dijkstra, Gerard ;

Oldenburg, Bas ;

Lowenberg, Mark ;

Bodegraven, Adriaan A. ;

van der Meulen-de Jong, Andrea E. ;

Boer, Nanne K. H. ;

Srivastava, Nidhi ;

West, Rachel L. ;

Romkens, Tessa E. H. ;

Horje, Carmen S. Horjus Talabur ;

Jansen, Jeroen M. ;

van der Woude, C. Janneke ;

Hoekstra, Jildou ;

Weersma, Rinse K. ;

van Schaik, Fiona D. M. ;

Hoentjen, Frank ;

Pierik, Marieke J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) :880-888

[7] Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations [J].

Casellas, Francesc ;

Guinard Vicens, Daniel ;

Garcia-Lopez, Santiago ;

Gonzalez-Lama, Yago ;

Arguelles-Arias, Federico ;

Barreiro-de Acosta, Manuel ;

Marin Sanchez, Laura ;

Manuel Mendive, Juan ;

Saldana, Roberto ;

Cabez, Ana ;

Gomez, Susana ;

Loza, Estibaliz .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (12) :1514-1522

[8] Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry [J].

Chaparro, Maria ;

Garre, Ana ;

Mesonero, Francisco ;

Rodriguez, Cristina ;

Barreiro-de Acosta, Manuel ;

Martinez-Cadilla, Jesus ;

Arroyo, Maria T. ;

Mancenido, Noemi ;

Sierra-Ausin, Monica ;

Vera-Mendoza, Isabel ;

Jose Casanova, Maria ;

Nos, Pilar ;

Gonzalez-Munoza, Carlos ;

Martinez, Teresa ;

Bosca-Watts, Maia ;

Calafat, Margalida ;

Busquets, David ;

Girona, Eva ;

Llao, Jordina ;

Dolores Martin-Arranz, Maria ;

Piqueras, Marta ;

Ramos, Laura ;

Suris, Gerard ;

Bermejo, Fernando ;

Carbajo, Ana Y. ;

Casas-Deza, Diego ;

Fernandez-Clotet, Agnes ;

Garcia, Maria J. ;

Ginard, Daniel ;

Gutierrez-Casbas, Ana ;

Hernandez, Luis ;

Lucendo, Alfredo J. ;

Marquez, Lucia ;

Merino-Ochoa, Olga ;

Rancel, Francisco J. ;

Taxonera, Carlos ;

Lopez Sanroman, Antonio ;

Rubio, Saioa ;

Domenech, Eugeni ;

Gisbert, Javier P. .

JOURNAL OF CROHNS & COLITIS, 2021, 15 (01) :35-42

[9] Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease [J].

Chen, Zhiwei ;

Wang, Xiaodong ;

Ye, Shuang .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03) :291-293

[10] Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis [J].

Colombel, Jean-Frederic ;

Osterman, Mark T. ;

Thorpe, Andrew J. ;

Salese, Leonardo ;

Nduaka, Chudy I. ;

Zhang, Haiying ;

Lawendy, Nervin ;

Friedman, Gary S. ;

Quirk, Daniel ;

Su, Chinyu ;

Reinisch, Walter .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (01) :116-+

← 1 2 3 4 5 6 7 →